The investigators propose to use clinically validated patient avatar technology ("PDXovo") that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.
The primary goal of this feasibility study is to determine the percentage of patients for whom PDXs are successfully generated within 7-10 days. This will give the investigators an indication of the success rate for providing patients with actionable information if this PDX technology were to be implemented in the clinic. Since the PDXs will also receive the same drug as the patient, there is an opportunity to assess the agreement between the clinical response and the PDX response. As a secondary goal, the response of PDXs will be compared to the patient's response to systemic therapy, as measured using the objective response rate at 12 weeks +/- 4 weeks (ORR, measured using RECIST 1.1 criteria).
Study Type
OBSERVATIONAL
Enrollment
25
Not an interventional study
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
RECRUITINGDetermine the tumor take rate in PDX
perform a feasibility study to determine the tumor take rate(s) in PDXs generated from needle core biopsies collected from metastatic breast cancer patients
Time frame: 7-10 days
Compare response rates of PDXs & with that of the patient from whom the PDX was derived
The response of PDXs will be compared to the patient's response to systemic therapy, as measured using the objective response rate.
Time frame: 8 to 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.